Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Net Margin (2020 - 2026)

Journey Medical filings provide 6 years of Net Margin readings, the most recent being 8.07% for Q4 2025.

  • On a quarterly basis, Net Margin fell 2060.0% to 8.07% in Q4 2025 year-over-year; TTM through Dec 2025 was 18.85%, a 765.0% increase, with the full-year FY2025 number at 18.67%, up 794.0% from a year prior.
  • Net Margin hit 8.07% in Q4 2025 for Journey Medical, up from 13.6% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 109.88% in Q3 2023 to a low of 124.17% in Q4 2021.
  • Median Net Margin over the past 5 years was 28.15% (2025), compared with a mean of 33.23%.
  • Biggest five-year swings in Net Margin: crashed -14240bps in 2021 and later surged 17243bps in 2023.
  • Journey Medical's Net Margin stood at 124.17% in 2021, then skyrocketed by 36bps to 80.06% in 2022, then surged by 82bps to 14.05% in 2023, then surged by 189bps to 12.54% in 2024, then plummeted by -164bps to 8.07% in 2025.
  • The last three reported values for Net Margin were 8.07% (Q4 2025), 13.6% (Q3 2025), and 25.29% (Q2 2025) per Business Quant data.